CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly ...

In 2022, Gan & Lee also introduced a pre-filled insulin glargine pen in Pakistan, marking the first biosimilar of its type in the country. The newly approved cartridge further strengthens its ...

The first insulin biosimilar, Semglee (insulin glargine-yfgn), received approval in June 2020. 2 In July 2021, it also became the first biosimilar to receive an interchangeability designation from ...

Find patient medical information for Insulin Glargine on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Insulin icodec is an investigational once-weekly basal insulin analogue for diabetes management. We conducted a 78-week randomized, open-label, treat-to-target phase 3a trial (including a 52-week m ...

LEHI, Utah--(BUSINESS WIRE)--Civica, Inc. (Civica, Civica Rx) today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable ...

Tresiba for type 1 diabetes in adults: Lantus for type 1 diabetes in adults: Forms • solution in a 10-mL multiple-use vial, given by subcutaneous injection • solution in a 3-mL FlexTouch pen ...

Lannett has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin ...

TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen ...